Vascular endothelial growth factor (VEGF-A) is the principal angiogenic promoter in most, if not all, cancers acting primarily on endothelial cells through its cognate receptors VEGF-R1 and VEGF-R2. VEGF is upregulated by hypoxia (Shweiki et al, 1992) , and by overexpression of oncogenes such as mutant ras (Rak et al, 1995) and c-myc (Mezquita et al, 2005) in tumours, and stimulates the migration of endothelial cells, sprouting of blood vessels, and generation of new vessels from existing vasculature in tumours (reviewed in Ferrara, 2004) . The resulting sustained blood flow, oxygen supply and waste removal enables more rapid growth of the tumour. Anti-VEGF therapy is now an additional therapeutic strategy to surgery, chemotherapy and radiotherapy, and recent trials of antibodies to VEGF as adjuvant therapy have shown significant clinical benefit in colorectal cancer (Hurwitz et al, 2004) , renal carcinoma, non small cell lung, ovarian and other cancers.
Vascular endothelial growth factor is generated as multiple isoforms by alternative splicing of mRNA from 8 exons (Houck et al, 1991) . Conventional VEGF isoforms are pro-angiogenic, propermeability vasodilators. These isoforms contain exons 1 -5 and 8a, with a variable contribution from exons 6a, 6b, 7a, and 7b, resulting in a family of peptides identified numerically by their amino-acid content, each with different heparin-binding properties (Houck et al, 1991) . These are generically identified as VEGF xxx , where xxx refers to the number of amino acids. In 2002 (Bates et al, 2002) and 2004 (Woolard et al, 2004) we identified a sister family of isoforms of identical lengths and exon structure apart from the C-terminal exon in which distal splicing results in an alternate open-reading frame of six amino acids (exon 8b rather than 8a, SLTRKD vs CDKPRR) -generically referred to as VEGF xxx b (e.g. VEGF 165 b, VEGF 121 b (Perrin et al, 2005) , VEGF 189 b (Miller-Kasprzak and Jagodzinski, 2008) ). These isoforms are antiangiogenic and downregulated in renal tumours and metastatic melanoma (Bates et al, 2002; Pritchard-Jones et al, 2007) . This antiangiogenic activity, generated by receptor binding but only weak receptor activation (Cebe Suarez et al, 2006) and inhibition of downstream VEGF-R2 signalling, has led to the hypothesis that VEGF 165 b, or manipulation of C-terminal VEGF splicing to enhance more distal splicing, may be useful therapeutic tools in cancer.
We have previously shown that VEGF 165 b is present in a range of normal tissues (Bates et al, 2002; Woolard et al, 2004) and there is a downregulation of the antiangiogenic VEGF 165 b protein in malignant prostate cancer (Woolard et al, 2004) and metastatic melanoma (Pritchard-Jones et al, 2007) and mRNA in renal carcinoma (Bates et al, 2002) . We also showed that VEGF 165 expressing tumours grew faster than VEGF 165 b expressing tumours, suggesting that VEGF 165 b was not angiogenic. Moreover, we showed that tumours in which VEGF 165 b expressing cells were mixed with VEGF 165 expressing cells grew more slowly than cells only expressing VEGF 165 (but more quickly than cells expressing VEGF 165 b alone). This latter finding rules out a possibility that VEGF 165 b could be angiogenic in the presence of VEGF 165 . However, neither that, nor any other study, has shown whether VEGF 165 b can inhibit tumour growth, whether it can inhibit VEGF 165 -mediated tumour growth, or whether it can do so by inhibiting angiogenesis.
In this study, we have examined the effect of VEGF 165 b overexpression on tumour growth, and VEGF 165 -mediated angiogenesis of prostate and renal cell carcinoma and on growth of Ewing's sarcoma cell and metastatic melanoma in xenografted mouse models.
MATERIALS AND METHODS

Human tissue and RT -PCR of human TURP chips
Frozen prostate chips were obtained from patients undergoing transurethral resection of the prostate (TURP) for lower urinary tract symptoms with benign prostatic hyperplasia and advanced prostate cancer (stage T3 Nx M0-1; UICC2002). The use of tissue was approved by the NBHST Ethical Committee.
Fifty to 100 mg of 26 TURP tissue (nine malignant, 17 benign prostatic hypertrophy) was homogenised in Trizol reagent (Life Technologies Inc., Rockville, MD, USA) and mRNA was extracted by using the method of (Chomczynski and Sacchi, 1987) . Eight microliters of RNA were treated with RNase free DNase (Promega, Madison, WI, USA) according to the manufacturer's guidelines to prevent genomic DNA contamination and mRNA was reverse transcribed using Moloney murine leukaemia virus reverse transcriptase and poly-d(T). cDNA was then amplified using intron spanning primers that detect VEGF 165 b only, even in the presence of 1000 fold greater concentration of VEGF 165 mRNA (Bates et al, 2002) . The cDNA was amplified using 1 mM intronspanning primers designed to detect VEGF xxx b (Bates et al, 2002) (Exon 4, 5 0 -GAGATGAGCTTCCTACAGCAC-3 0 and (Exon8b/7, 5 0 -TT AAGCTTTCAGTCTTTCCTGGTGAGAGATCTGCA-3 0 ) or VEGF xxx with exon 8a (5 0 -CACCGCCTCGGCTTGTCACAT-3 0 ), together with 1.2 mM MgCl 2 , 200 mM dNTPs, and 1 unit of Taq DNA polymerase (Abgene), cycled 35 times, at 941C for 30 s, 631C for 30 s and 721C for 60 s. b2-microglobulin was used as control amplification (b2 forward primer 5 0 -GCATCATGGAGGTTTGAAGATG-3 0 , b2 reverse 5 0 -TAAGTTGCCAGCCCTCCTAGAG-3 0 ) at 551C annealing temperature leading to a 220 bp product. Full-length VEGF 165 b or VEGF 165 in pcDNA3 vector were used as positive and negative controls. PCR products were run on 3% agarose gels. PCR bands were excised and extracted using Qiaex (Qiagen, Crawley, UK), cloned using a TOPO TA Cloning s Kit (Invitrogen, Paisley, UK) and confirmed by sequencing. (Perrin et al, 2005) or a commercial panVEGF ELISA (Duoset, R&D Systems), that detects all isoforms of VEGF-A, to validate expression levels in selected cells. ELISA was performed either according to manufacturers instructions or as previously described (Woolard et al, 2004) . Conditioned media from 200 000 cells was collected and was analysed by ELISA after 48 h incubation. Mel57 cells were transfected with plasmid pIRESneo containing the VEGF 165 or VEGF 165 b cDNA essentially as described before (Kusters et al, 2007) .
Establishment of overexpressing tumour cells
Migration of cells with conditioned media
Cultured supernatants from TC71, empty vector transfected TC71 or TC71/VEGF 165 b cells were collected. Transwells (Costar, Cambridge, MA, USA) were pretreated with serum-free medium at 371C for 1 h before seeding with human dermal microvascular endothelial cells, (HMVECs)at 1 Â 10 5 per well in 100 ml endothelial basal media (Cambrex, Baltimore, MD, USA) with 0.1% fetal bovine serum. These cells are commercially available cells generated from human foreskin tissue. The transwells were then inserted into 24-well plates containing 600 ml of conditioned medium and incubated at 371C for 6 h to allow HMVEC cells to migrate. Cells on the upper side of the filter were removed with cotton swabs. Migrated cells on the lower side of the filter were fixed and stained with haematoxylin and eosin. The number of migrated cells was counted under a binocular microscope. 
In vitro growth analysis of cells
For direct counting and proliferation of transfected CAKI cells, 30 000 cells per 24 well were seeded out in triplicates. Cells were maintained in media supplemented with 0.01% or 10% FCS and were counted after 24 or 48 h. The doubling time for each cell population was calculated using Prism software. The metabolic rate was analysed by seeding 5000 cells per 96 well in media supplemented with 0.01% FCS. After 24 or 48 h 50 ml of metabolic reagent was added (CellTiter 96 s Aqueous One solution, Promega, Madison, WI, USA). Cells were incubated for 4 h at 371C and analysed at 490 nm.
Animal housing and xenograft model
One million Ewing sarcoma or Mel57, 8 million CAKI, 3 million PC3 overexpressing cells were injected subcutaneously into the back of unanaesthetised nude mice in 100 ml sterile PBS. Xenotransplanted tumours were measured by calliper and tumour volume was calculated according to (length Â width Â (length þ width)/2). Mice were culled by cervical dislocation when tumours reached 16 mm in any direction and organs and tumours were removed and snap-frozen or fixed in 4% PFA followed by paraffin embedding and 5 mm sections were generated and stained with CD31/PECAM. Slides were boiled for 10 min in 0.01 M sodium citrate boiling, followed by blocking in 5% goat serum for 1 h, overnight incubation with 2.5 mg ml À1 anti-mouse PECAM antibody (Pierce Endogen) and for 1 h in 5 mg ml À1 ALEXA Fluor 488 goat anti hamster IgG (Invitrogen, Molecular Probes). Vessels were counted in six different fields at Â 20 magnification and verified at Â 40 magnification. Nude mice were kept under appropriate specific pathogen-free housing facilities according to government guidelines and procedures were carried out according to national guidelines and regulations.
Statistical analysis
Statistical analysis was performed using Prism. All data are given as mean ± s.e.m. if not otherwise stated. Number of benign TUR and malignant chips expressing VEGF 165 b was compared using Fisher's exact test. For tumour growth one-way analysis of variance (ANOVA) followed by Newman -Keuls' post hoc test (prostate) or two-way ANOVA followed by Bonferroni post hoc test (renal carcinoma) were used as data allowed. Weight, blood score, proliferation, cell doubling and metabolic rate were analysed by one-way ANOVA followed by Newman -Keuls' multiple comparison post hoc test. Po0.05 was considered significant.
RESULTS
VEGF 165 b is downregulated in malignant prostate tumours compared to benign prostate tissue and reduced tumour growth in xenograft model RNA was extracted from human prostate chips from patients undergoing TURP and expression of VEGF 165 and VEGF 165 b mRNA was analysed by isoform specific PCR. Expression of VEGF 165 b was found in 10 out of 11 benign samples and VEGF 165 was also present in 10 out of 11 (see Figure 1A) . In malignant prostate on the other hand, VEGF 165 b was only found in four out of nine, whereas the VEGF 165 expression was found in eight out of nine (see Figure 1B) .
Human prostate cancer cells, PC3 cells, were transfected with control, VEGF 165 b, VEGF 165 expression plasmids, or a combination of the two and injected into nude mice. The tumour volume was monitored over time and at day 18 the tumour volumes were significantly different (Po0.05). Figure 2A) , and VEGF 165 -expressing tumours resulted in larger, bloody tumours after 29 days (see Figure 2B ), VEGF 165 bexpressing tumours, while they did grow (see Figure 2C) were smaller, and less bloody. Cells expressing both isoforms also resulted in small, relatively blood-free tumours that were not different from the VEGF 165 b-expressing tumours (see Figure 2D ). Figure 2E shows that VEGF 165 b-expressing tumours grew significantly slower than VEGF 165 -expressing tumours (overall Po0.001, VEGF 165 vs VEGF 165 b Po0.05 at day 27, VEGF 165 vs both Po0.05 day 24 and Po0.001 day 27). No significant difference was found between tumours formed from cells expressing VEGF 165 and control or between those expressing VEGF 165 b and both VEGF isoforms.
Upon excision of the tumours, they were weighed and scored blindly for blood content. VEGF 165 -expressing tumours were significantly larger (see Figure 2F ) than control and VEGF 165 bexpressing tumours, which also resulted in a significant reduction of tumour volume (Po0.05 VEGF 165 vs both isoforms or VEGF 165 b). There was a non-significant reduction in tumour volume for VEGF 165 b-expressing tumours compared with control transfected. Macroscopically the tumours differed with more blood in VEGF 165 -expressing tumours compared to any other of the groups (Po0.01, VEGF 165 vs either of the other groups, Figure 2G ). Similar data was observed with a smaller initial tumour cell injection (2 Â 10 6 cells, data not shown). The growth rates of the transfected CAKI cells were analysed. There was no difference in the proliferation as measured by direct counting of cells (see Figure 3A and B) or analysis of metabolic rate (see Figure 3C ). Both experiments were performed in the presence of serum with the same results (data not shown).
These results indicate that VEGF 165 b overexpression reduced tumour growth in renal cell carcinoma cells grown in mice even in the presence of VEGF 165 . The tumour inhibition by VEGF 165 b appears not to be through reduction in tumour cell proliferation.
VEGF 165 b overexpression reduced Ewing's sarcoma growth and tumour-conditioned media reduced endothelial cell proliferation and migration Injection of TC71 Ewing's sarcoma cells overexpressing VEGF 165 b subcutaneously into the back of nude mice resulted in tumours that grew significantly slower than control cells over a time period of 29 days (see Figure 4A ). To determine whether VEGF 165 b secreted from the tumour cells was active on the cells that go on to form blood vessels, conditioned media from the Ewing's sarcoma cells, TC71 cells, overexpressing VEGF 165 b was used to study migration of human microvascular vein endothelial cells, HMVEC. Fetal calf serum resulted in migration of HMVEC as expected (see Figure 4B ), and conditioned media from control-transfected tumour cells induced a similar level of migration of HMVEC (see Figure 4C ). VEGF 165 b overexpressing tumour cells resulted in less migration compared to tumour-conditioned media or controlstimulated cells (see Figure 4D) .
To determine whether VEGF 165 b could inhibit growth of endothelial cells, DNA synthesis in HMVEC was measured. 
VEGF 165 increased [
3 H]-incorporation into HMVECs when added to control tumour cell-conditioned medium. VEGF 165 b-conditioned media did not increase DNA synthesis of HMVEC cells and reduced VEGF 165 -mediated DNA synthesis (see Figure 4E ). However, VEGF 165 b did not reduce proliferation below the level of control-conditioned media, indicating that the inhibition of proliferation was specific for VEGF 165 -mediated proliferation.
Rate of tumour growth depends upon the VEGF isoform expression
The results above suggest that switching expression of VEGF from VEGF 165 to VEGF 165 b might result in reduced tumour growth rates. To determine whether this was the case a VEGF-deficient melanoma cell line (Mel57), which normally grows slowly by cooption of existing vasculature (Westphal et al, 2000) was transfected with VEGF 165 or VEGF 165 b, and implanted subcutaneously. Figure 5 shows that whereas VEGF 165 -expressing tumours rapidly grew, VEGF 165 b expressing-tumours were very slow growing, matching that of the previously published co-option dependent parental cell line, indicating that switching expression from VEGF 165 to VEGF 165 b by altering splicing may be a useful therapeutic strategy.
VEGF 165 b inhibits VEGF 165 -mediated tumour vessel ingrowth
To examine the mechanism for the reduction of tumour growth in vivo and the proposed anti-angiogenic effect of VEGF 165 b, tumour vessels were visualised by PECAM staining of excised tumour sections. In the CAKI tumours there was a significant increase in microvascular density from 7.03 ± 0.86 per high power field in control ( Figure 6A ) to 8.37±1.06 in VEGF 165 -expressing tumours ( Figure 6B ). In contrast, there was a significant reduction in MVD to 2.17 ± 0.65/hpf in VEGF 165 b-expressing tumours (Po0.01 compared with control Figure 6C ), indicating that VEGF 165 b inhibited vessel growth in CAKI tumours. This was also significantly lower than VEGF 165 (Po0.001). Furthermore, tumours in which VEGF 165 b and VEGF 165 were coexpressed also had significantly reduced MVD (2.98±0.56, Figure 6D were seen in PC3 cells (Control 8.13 ± 0.40, VEGF 165 7.17 ± 1.66, VEGF 165 b 0.78 ± 0.78, VEGF 165 þ VEGF 165 b 0.64 ± 0.64. see Figure  6F -J).
DISCUSSION
VEGF has been generally considered in over 20 000 papers since 1990 as a pro-angiogenic tumour-enhancing endothelial-specific growth factor (Ferrara, 2002) and successful antiangiogenic agents have been directed at VEGF in cancer and eye disease (Gragoudas et al, 2004; Hurwitz et al, 2004) . In 2002, we identified for the first time that an alternative splice site in the terminal exon 8 of the VEGF mRNA could be used to generate an alternative isoform (Bates et al, 2002) , VEGF 165 b, which we subsequently showed to be one of a family of VEGF isoforms generated by C-terminal distal splice site selection, the VEGF xxx b family of isoforms (Perrin et al, 2005) . However, while the conventional exon 8a containing isoforms predominate in the pathological angiogenic phenotype seen in tumours, proliferative retinopathy, arthritis etc (Ferrara, 2002) , the exon 8b containing isoforms, which are anti-angiogenic in vivo are downregulated in a number of pathologies (Bates et al, 2002; Woolard et al, 2004; Cebe Suarez et al, 2006; Schumacher et al, 2007) . Loss of the C-terminal domain (resulting in VEGF 159 ) results in a loss of angiogenic activity of the VEGF molecule, but does not result in inhibition of angiogenesis (Cebe Suarez et al, 2006) . The mechanism of action through which VEGF xxx b prevents tumour growth is not yet fully elucidated. However, it is clear from previous studies that VEGF 165 b is able to bind both VEGFR-1 (Cebe Suarez et al, 2006) and VEGFR-2 (Woolard et al, 2004) , but initiates only weak signalling of the receptor to induce tyrosine phosphorylation (Woolard et al, 2004; Cebe Suarez et al, 2006) , and is unable to induce a behavioural change in large vessel endothelial cells that mimic that shown by microvascular endothelial cells in vivo during angiogenesis (Woolard et al, 2004; Cebe Suarez et al, 2006) . This study indicates for the first time that VEGF 165 b can exert its action by preventing tumour secreted endothelial growth factors (presumably VEGF 165 , or other VEGF xxx isoforms) from acting on microvascular endothelial cells.
Several studies have shown that VEGF expression in the malignant tissue and/or plasma correlates with aggressive disease (reviewed in Delongchamps et al, 2006) and VEGF mRNA and protein are upregulated in prostate carcinoma (Ferrer et al, 1997; Jackson et al, 1997) . Our data indicate that there is a switch in VEGF expression allowing the pro-angiogenic VEGF xxx isoforms to dominate within malignant prostate and renal cell carcinoma, allowing the tumours to develop their own blood supply.
The current findings indicate that VEGF 165 b may have a therapeutic role in cancer treatment, by altering splicing of the VEGF gene to result in over-expression of VEGF 165 b at the expense of VEGF 165 . The latter mechanisms (control of splicing at the C-terminal end of the VEGF gene), is therefore one of intense interest, but unfortunately almost nothing has been published concerning the regulation of splicing of the VEGF gene. The vascular phenotype in both pathological and physiological angiogenesis may therefore depend on the balance of VEGF isoforms. We have speculated then that in addition to malignant change related to cell turnover/survival (which may also be determined by splicing (Venables, 2004 ) a second event occurs in which splicing control of many factors with pre-and antiangiogenic splice variants occur to allow the malignant disease to progress (Ladomery et al, 2006) .
To conclude, these findings indicate that VEGF 165 b is able to inhibit growth of at least three different tumour types, and that the mechanism of inhibition is through inhibiting angiogenesis rather than a direct effect on tumour cell growth.
